Treatment of MIS-C in Children and Adolescents.

ABSTRACT:

Purpose of review

Different treatment approaches have been described for the management of COVID-19-related multisystem inflammatory syndrome in children (MIS-C), the pathogenesis of which has not yet been fully elucidated. Here, we comprehensively review and summarize the recommendations and management strategies that have been published to date.

Recent findings

MIS-C patients are treated with different regimens, mostly revolving around the use of immunomodulatory medications, including IVIG and glucocorticoids as first-tier therapy. Refractoriness to IVIG and glucocorticoids warrants a step-up of immunomodulatory therapy to biologic agents such as anakinra, tocilizumab, and infliximab.

Summary

We review the current evidence regarding the use of monotherapy versus co

SUBMITTER: Mahmoud S 

PROVIDER: S-EPMC8741532 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature